Related Experiment Videos
Bladder leiomyosarcoma following cyclophosphamide therapy for lupus nephritis
J B Thrasher1, G J Miller, J N Wettlaufer
1Department of Surgery, Fitzsimons Army Medical Center, Aurora, Colorado.
The Journal of Urology
|January 1, 1990
Summary
Long-term cyclophosphamide chemotherapy, used for lupus nephritis and rheumatoid arthritis, is linked to bladder leiomyosarcoma development. This study highlights the risk of secondary cancers from this chemotherapy in non-neoplastic conditions.
Area of Science:
- Oncology
- Urology
- Rheumatology
- Nephrology
Background:
- Cyclophosphamide is an alkylating agent used in chemotherapy.
- Previous concerns regarding cyclophosphamide's carcinogenicity were often based on its use in treating other neoplasms.
- The link between cyclophosphamide and secondary malignancies in non-neoplastic conditions requires further investigation.